Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder

Stock Information for Clearmind Medicine Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Clearmind Medicine Inc.

Clearmind Medicine Announces 1-for-10 Reverse Share Split
Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications
Clearmind Medicine CEO Dr. Adi Zuloff-Shani named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C.
Clearmind Medicine Announces "Inside MEAI" Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial
Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD
Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation
Clearmind Medicine Welcomes President Trump's Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health Care
Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.